Plain-English translation of NCT06201611 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether a medication called Nebivolol, which is normally used to treat high blood pressure, can help slow or reverse nerve damage caused by diabetes. Researchers believe this medication may work by improving blood flow and reducing inflammation in damaged nerves. You would be randomly assigned to receive either this medication, a combination of two existing neuropathy treatments, or standard pain management alone.
Diabetic nerve damage (neuropathy) causes pain, numbness, and weakness, and current treatments mainly manage symptoms rather than actually healing the nerves. This trial explores whether this medication could potentially repair nerve damage instead of just treating the pain.
You likely qualify if…
You likely don't qualify if…
You would visit the research center at the start and then at week 24 (about 6 months). At each visit, you'll have nerve tests, blood work, and possibly scans to measure how your nerves are healing. Depending on which group you're randomly assigned to, you'll either take the new medication daily (starting at a low dose and gradually increasing it), take two combination medications, or receive standard pain treatment—all while your doctors monitor your progress and measure changes in your nerve function.
AI-generated summary from trial data · Jun 1, 2026 · Not medical advice
India